{"analyses":[{"ciLowerLimit":"0.85","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.46","estimateComment":"Reference level = placebo arm","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.213","paramType":"Hazard Ratio (HR)","paramValue":"1.11","statisticalComment":"One-sided test","statisticalMethod":"Gray's test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"73.2","upperLimit":"86.3","value":"80.7"},{"groupId":"OG001","lowerLimit":"75.0","upperLimit":"90.3","value":"84.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"description":"Third PSA recurrence rates (i.e. second PSA failure on study) were estimated by the cumulative incidence method, with failure defined as PSA value of 0.5ng/ml or higher or any disease progression after starting salvage hormone therapy. Patients alive without third PSA recurrence at time of analysis were censored. Death without third PSA recurrence was treated as a competing risk. Four-year follow-up was required of all patients, but twelve-year rates were reported. Patients are followed until death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy (64.8 Gy) + placebo (daily 2 years)","id":"OG000","title":"Placebo"},{"description":"Radiation therapy (64.8 Gy) + bicalutamide (150 mg daily 2 years)","id":"OG001","title":"Bicalutamide"}],"paramType":"NUMBER","populationDescription":"Eligible patients who did not withdraw consent and who started salvage hormone therapy.","reportingStatus":"POSTED","timeFrame":"From start of salvage hormone therapy to 12 years.","title":"Third PSA Recurrence (12-year Rates Reported)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}